Axial Lumbosacral Interbody Fusion

Policy # 00236
Original Effective Date: 04/15/2009
Current Effective Date: 11/08/2020

Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc. (collectively referred to as the “Company”), unless otherwise provided in the applicable contract. Medical technology is constantly evolving, and we reserve the right to review and update Medical Policy periodically.

Note: Interspinous and Interlaminar Stabilization Distraction Devices (Spacers) is addressed separately in medical policy 00221.

Note: Interspinous Fixation (Fusion) Devices is addressed separately in medical policy 00679.

Services Are Considered Investigational
Coverage is not available for investigational medical treatments or procedures, drugs, devices or biological products.

Based on review of available data, the Company considers axial lumbosacral interbody fusion (axial LIF) to be investigational.*

Background/Overview

Interbody Fusion
Interbody fusion is a surgical procedure that fuses 2 adjacent vertebral bodies of the spine. Lumbar interbody fusion may be performed in patients with spinal stenosis and instability, spondylolisthesis, scoliosis, following a discectomy, or for adjacent-level disc disease.

Axial Lumbosacral Interbody Fusion
Axial lumbosacral interbody fusion (also called presacral, transsacral, or paracoccygeal interbody fusion) is a minimally invasive technique designed to provide anterior access to the L4-S1 disc spaces for interbody fusion while minimizing damage to muscular, ligamentous, neural, and vascular structures. It is performed under fluoroscopic guidance.

An advantage of axial lumbosacral interbody fusion is that it preserves the annulus and all paraspinous soft tissue structures. However, there is an increased need for fluoroscopy and an inability to address intracanal pathology or visualize the discectomy procedure directly.
Complications of the axial approach may include perforation of the bowel and injury to blood vessels and/or nerves.

**FDA or Other Governmental Regulatory Approval**

**U.S. Food and Drug Administration (FDA)**

The U.S. FDA has cleared for marketing multiple anterior spinal intervertebral body fixation device systems through the 510(k) pathway (See Table 1). The systems are not intended to treat severe scoliosis, severe spondylolisthesis (grades 3 and 4), tumor, or trauma. The devices are also not meant for vertebral compression fractures or any other condition in which the mechanical integrity of the vertebral body is compromised. Their usage is limited to anterior supplemental fixation of the lumbar spine at the L5-S1 or L4-S1 disc spaces in conjunction with a legally marketed facet or pedicle screw systems. FDA product code: KWQ.

**Table 1. Select Anterior Spinal Intervertebral Body Fixation Orthoses Cleared by U.S. Food and Drug Administration**

<table>
<thead>
<tr>
<th>Orthotic</th>
<th>Manufacturer</th>
<th>Date Cleared</th>
<th>510(k) No.</th>
</tr>
</thead>
<tbody>
<tr>
<td>TranS1®‡ AxiaLIF™‡ System</td>
<td>TranS1</td>
<td>12/04</td>
<td>K040426</td>
</tr>
<tr>
<td>• For patients requiring fusion to treat pseudoarthrosis, unsuccessful previous fusion, spinal stenosis, spondylolisthesis (grade 1 or 2), or degenerative disc disease limited to anterior supplemental fixation of L5-S1 in conjunction with legally marketed pedicle screws</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>TranS1 AxiaLIF System</td>
<td>TranS1</td>
<td>06/05</td>
<td>K050965</td>
</tr>
<tr>
<td>• Indication modified to include facet screws</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
### TranS1 AxiaLIF® II System

- For patients requiring fusion to treat pseudoarthrosis, unsuccessful previous fusion, spinal stenosis, spondylolisthesis (grade 1 or 2), or degenerative disc disease limited to anterior supplemental fixation of L4-S1 in conjunction with legally marketed facet and pedicle screws

<table>
<thead>
<tr>
<th>TranS1 AxiaLIF® II System</th>
<th>TranS1</th>
<th>04/08</th>
<th>K073643</th>
</tr>
</thead>
</table>

### TranS1 AxiaLIF® 2L System

- Indication unchanged, marketed with branded bone morphogenetic protein

<table>
<thead>
<tr>
<th>TranS1 AxiaLIF® 2L System</th>
<th>TranS1</th>
<th>01/10</th>
<th>K092124</th>
</tr>
</thead>
</table>

### TranS1 AxiaLIF® Plus System

- Intended to provide anterior stabilization of the L5-S1 or L4-S1 spinal segment(s) as an adjunct to spinal fusion
- This device’s instruments are used for independently distracting the L5-S1 or L4-S1 vertebral bodies and inserting bone graft material (Dt3M, autograft or autologous blood) into the disc space.
- Use limited to anterior supplemental fixation of the lumbar spine at L5-S1 or L4-S1 in conjunction with use of legally marketed facet screw or pedicle screw systems at the same levels that are treated with AxiaLIF

<table>
<thead>
<tr>
<th>TranS1 AxiaLIF® Plus System</th>
<th>TranS1</th>
<th>03/11</th>
<th>K102334</th>
</tr>
</thead>
</table>
Axial Lumbosacral Interbody Fusion

Policy # 00236
Original Effective Date: 04/15/2009
Current Effective Date: 11/08/2020

Adapted from the U.S. FDA (2007, 2008).
FDA: Food and Drug Administration.

**Rationale/Source**
Axial lumbosacral interbody fusion (also called presacral, transsacral, or paracoccygeal interbody fusion) is a minimally invasive technique designed to provide anterior access to the L4-S1 disc spaces for interbody fusion while minimizing damage to muscular, ligamentous, neural, and vascular structures. It is performed under fluoroscopic guidance.

For individuals who have degenerative spine disease at the L4-S1 disc spaces who receive axial lumbosacral interbody fusion, the evidence includes a comparative systematic review of case series and a retrospective comparative study. Relevant outcomes are symptoms, functional outcomes, quality of life, and treatment-related morbidity. The systematic review found that fusion rates were higher following transforaminal lumbosacral interbody fusion than following axial lumbosacral interbody fusion, although this difference decreased with use of bone morphogenetic protein or pedicle screws. The findings of this systematic review were limited by the lack of prospective comparative studies and differences in how fusion rates were determined. Studies have suggested that complication rates may be increased with 2-level axial lumbosacral interbody fusion. Controlled trials with clinical outcome measures are needed to better define the benefits and risks of this procedure compared with treatment alternatives. The evidence is insufficient to determine the effects of the technology on health outcomes.

**Supplemental Information**

**Clinical Input from Physician Specialty Societies and Academic Medical Centers**
While the various physician specialty societies and academic medical centers may collaborate with and make recommendations during this process, through the provision of appropriate reviewers, input received does not represent an endorsement or position statement by the physician specialty societies or academic medical centers, unless otherwise noted.

In response to requests, input was received from 2 specialty medical societies and 3 academic medical centers while this policy was under review in 2011. Input considered axial lumbosacral interbody fusion to be investigational.
Axial Lumbosacral Interbody Fusion

Policy # 00236
Original Effective Date: 04/15/2009
Current Effective Date: 11/08/2020

Practice Guidelines and Position Statements

North American Spine Society
In 2014, the North American Spine Society published guidelines on the treatment of degenerative spondylolisthesis. The North American Spine Society gave a grade B recommendation for surgical decompression with fusion in patients with spinal stenosis and spondylolisthesis. The guidelines discussed posterolateral fusion, 360º fusion, and minimally invasive fusion; it did not address axial lumbosacral interbody fusion.

National Institute for Health and Care Excellence
In 2011, the National Institute for Health and Care Excellence (NICE) provided guidance on transaxial interbody fusion in the lumbosacral spine. The guidance stated that current evidence on the efficacy of transaxial interbody lumbosacral fusion is “limited in quantity but shows symptom relief in the short term in some patients. Evidence on safety shows that there is a risk of rectal perforation.” The Institute encouraged “further research into transaxial interbody lumbosacral fusion. Research outcomes should include fusion rates, pain and functional scores, quality of life measures, and the frequency of both early and late complications.”

In July 2018, the NICE guidance was updated and replaced by evidence-based recommendations on transaxial interbody lumbosacral fusion for low back pain in adults. The recommendation, based on a literature review conducted in December 2017, states, “Evidence on the safety of transaxial interbody lumbosacral fusion for severe chronic low back pain shows that there are serious but well-recognised complications. Evidence on efficacy is adequate in quality and quantity. Therefore, this procedure may be used provided that standard arrangements are in place for clinical governance, consent and audit. This procedure should only be done by a surgeon with specific training in the procedure, who should carry out their initial procedures with an experienced mentor.”

U.S. Preventive Services Task Force Recommendations
Not applicable.

Medicare National Coverage
There is no national coverage determination. In the absence of a national coverage determination, coverage decisions are left to the discretion of local Medicare carriers.

©2020 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.

Page 5 of 10
Axial Lumbosacral Interbody Fusion

Policy # 00236
Original Effective Date: 04/15/2009
Current Effective Date: 11/08/2020

Ongoing and Unpublished Clinical Trials
An unpublished trial that might influence this review is shown in Table 2.

Table 2. Summary of Key Trials

<table>
<thead>
<tr>
<th>NCT No.</th>
<th>Trial Name</th>
<th>Planned Enrollment</th>
<th>Completion Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>NCT01716182a</td>
<td>RAMP Study: A Prospective Randomized Study Comparing Two Lumbar Fusion Procedures</td>
<td>200</td>
<td>Jul 2014 (terminated) slow enrollment</td>
</tr>
</tbody>
</table>

NCT: national clinical trial.

* Denotes industry-sponsored or cosponsored trial.

References
Axial Lumbosacral Interbody Fusion

Policy #  00236
Original Effective Date:  04/15/2009
Current Effective Date:  11/08/2020


Policy History

Original Effective Date:  04/15/2009
Current Effective Date:  11/08/2020

04/02/2009  Medical Director review
04/15/2009  Medical Policy Committee approval. New policy.
04/08/2010  Medical Director review
04/21/2010  Medical Policy Committee approval. No change to coverage.
04/07/2011  Medical Policy Committee review
04/13/2011  Medical Policy Implementation Committee approval. No change to coverage.
04/12/2012  Medical Policy Committee review
04/25/2012  Medical Policy Implementation Committee approval. No change to coverage. References added.
04/04/2013  Medical Policy Committee review
Axial Lumbosacral Interbody Fusion

Policy # 00236
Original Effective Date: 04/15/2009
Current Effective Date: 11/08/2020

04/24/2013 Medical Policy Implementation Committee approval. Title changed. Entire policy redone to track BCBSA new policy.
03/06/2014 Medical Policy Committee review
03/19/2014 Medical Policy Implementation Committee approval. Coverage eligibility unchanged.
03/05/2015 Medical Policy Committee review
03/20/2015 Medical Policy Implementation Committee approval. Coverage eligibility unchanged.
06/02/2016 Medical Policy Committee review
06/20/2016 Medical Policy Implementation Committee approval. Coverage eligibility unchanged.
01/01/2017 Coding update: Removing ICD-9 Diagnosis Codes
06/01/2017 Medical Policy Committee review
06/21/2017 Medical Policy Implementation Committee approval. Coverage eligibility unchanged.
06/07/2018 Medical Policy Committee review
06/20/2018 Medical Policy Implementation Committee approval. Coverage eligibility unchanged.
06/06/2019 Medical Policy Committee review
06/19/2019 Medical Policy Implementation Committee approval. Coverage eligibility unchanged.
08/06/2020 Medical Policy Committee review
08/12/2020 Medical Policy Implementation Committee approval. Coverage eligibility unchanged.

Next Scheduled Review Date: 08/2021

Coding
The five character codes included in the Blue Cross Blue Shield of Louisiana Medical Policy Coverage Guidelines are obtained from Current Procedural Terminology (CPT®), copyright 2019 by the American Medical Association (AMA). CPT is developed by the AMA as a listing of descriptive terms and five character identifying codes and modifiers for reporting medical services and procedures performed by physician.
Axial Lumbosacral Interbody Fusion

Policy # 00236
Original Effective Date: 04/15/2009
Current Effective Date: 11/08/2020

The responsibility for the content of Blue Cross Blue Shield of Louisiana Medical Policy Coverage Guidelines is with Blue Cross and Blue Shield of Louisiana and no endorsement by the AMA is intended or should be implied. The AMA disclaims responsibility for any consequences or liability attributable or related to any use, nonuse or interpretation of information contained in Blue Cross Blue Shield of Louisiana Medical Policy Coverage Guidelines. Fee schedules, relative value units, conversion factors and/or related components are not assigned by the AMA, are not part of CPT, and the AMA is not recommending their use. The AMA does not directly or indirectly practice medicine or dispense medical services. The AMA assumes no liability for data contained or not contained herein. Any use of CPT outside of Blue Cross Blue Shield of Louisiana Medical Policy Coverage Guidelines should refer to the most current Current Procedural Terminology which contains the complete and most current listing of CPT codes and descriptive terms. Applicable FARS/DFARS apply.

CPT is a registered trademark of the American Medical Association.

Codes used to identify services associated with this policy may include (but may not be limited to) the following:

<table>
<thead>
<tr>
<th>Code Type</th>
<th>Code</th>
</tr>
</thead>
<tbody>
<tr>
<td>CPT</td>
<td>22586, 22899</td>
</tr>
<tr>
<td>HCPCS</td>
<td>No codes</td>
</tr>
<tr>
<td>ICD-10 Diagnosis</td>
<td>M43.00-M43.19, M48.06-M48.07, M51.06, M51.114-M51.117, M51.34-M51.37, M54.14-M54.17, M96.0, M99.23, M99.33, M99.43, M99.53, M99.63, M99.73, Z98.1</td>
</tr>
</tbody>
</table>

*Investigational – A medical treatment, procedure, drug, device, or biological product is Investigational if the effectiveness has not been clearly tested and it has not been incorporated into standard medical practice. Any determination we make that a medical treatment, procedure, drug, device, or biological product is Investigational will be based on a consideration of the following:

A. Whether the medical treatment, procedure, drug, device, or biological product can be lawfully marketed without approval of the U.S. Food and Drug Administration (FDA) and whether such approval has been granted at the time the medical treatment, procedure, drug, device, or biological product is sought to be furnished; or
Axial Lumbosacral Interbody Fusion

Policy #  00236  
Original Effective Date:  04/15/2009  
Current Effective Date:  11/08/2020

B. Whether the medical treatment, procedure, drug, device, or biological product requires further studies or clinical trials to determine its maximum tolerated dose, toxicity, safety, effectiveness, or effectiveness as compared with the standard means of treatment or diagnosis, must improve health outcomes, according to the consensus of opinion among experts as shown by reliable evidence, including:

1. Consultation with the Blue Cross and Blue Shield Association technology assessment program (TEC) or other nonaffiliated technology evaluation center(s);
2. Credible scientific evidence published in peer-reviewed medical literature generally recognized by the relevant medical community; or
3. Reference to federal regulations.

‡ Indicated trademarks are the registered trademarks of their respective owners.

NOTICE: If the Patient’s health insurance contract contains language that differs from the BCBSLA Medical Policy definition noted above, the definition in the health insurance contract will be relied upon for specific coverage determinations.

NOTICE:Medical Policies are scientific based opinions, provided solely for coverage and informational purposes. Medical Policies should not be construed to suggest that the Company recommends, advocates, requires, encourages, or discourages any particular treatment, procedure, or service, or any particular course of treatment, procedure, or service.